

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

2023 THIRD QUARTERLY REPORT

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) to provide shareholders of the Company and the public with the updated financial information of the Company. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The unaudited results (the “**Third Quarterly Report**”) of the Group for the nine months ended 30 September 2023 are provided. The financial information contained in the Third Quarterly Report was prepared in accordance with the Chinese Accounting Standards for Business Enterprises (“**CASs**”), and consists accounting data which has not been audited. Potential investors and shareholders of the Company are advised to pay attention to the underlying investment risks.

The Third Quarterly Report is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the Third Quarterly Report shall prevail.

By order of the Board

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Chairman

Shi Wenling

Beijing, the PRC, 30 October 2023

As at the date of this announcement, the executive Directors are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director is Mr. Wang Xin; and the independent non-executive Directors are Ms. Yao Lijie, Mr. Wong Tak Shing and Mr. Weng Jie.

* *For identification purposes only*

Stock Code: 688236

Stock Short Name: Chunli Medical

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

2023 Third Quarterly Report

The Board of Directors of the Company and all Directors undertake that this announcement contains no false record, misleading statement or material omission, and assume legal responsibility for the truthfulness, accuracy and completeness of its contents in accordance with law.

Important Notice:

The Board of Directors of the Company, the Board of Supervisors, the Directors, Supervisors, senior management warrant that the content of this quarterly report is true, accurate and complete and contains no false record, misleading statement or material omission, and jointly and severally assume legal responsibility for the content of this report.

The person in charge of the Company, the person in charge for accounting affairs of the Company and the person in charge of the accounting department (financial controller) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.

Whether the financial statements for the third quarter are audited?

Yes No

1. Key financial data

(A) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

Items	Current Reporting Period	Percentage change of the Current	From the beginning of the year to the	Percentage change of the period from

		Reporting Period as compared to the corresponding period of last year (%)	end of the Reporting Period	the beginning of the year to the end of the Reporting Period as compared to the corresponding period of last year (%)
Revenue	251,448,670.74	33.34	792,155,559.31	4.24
Net profit attributable to the shareholders of the listed company	54,545,916.88	3.45	180,622,954.88	-13.87
Net profit attributable to the shareholders of the listed company after deducting non- recurring profit or loss	51,431,151.23	106.11	161,750,047.30	-10.94
Net cash flows generated from operating activities	52,721,051.78	924.95	13,749,157.98	N/A
Basic earnings per share (yuan/share)	0.14	-	0.47	-14.55
Diluted earnings per share (yuan/share)	0.14	-	0.47	-14.55
Weighted average RONA (%)	1.99	Decrease by 0.05	6.52	Decrease by 1.68

2023 Third Quarterly Report

		percentage points		percentage points
Total investments in research and development	40,171,522.95	22.76	114,743,907.65	9.26
Percentage of research and development investment to revenue (%)	15.98	Decrease by 1.37 percentage points	14.49	Increase by 0.67 percentage points
	At the end of Current Reporting Period	At the end of last year		Percentage change at the end of this Reporting Period as compared to the end of last year (%)
Total assets	3,359,888,860.41	3,409,766,690.91		-1.46
Owners' equity attributable to the shareholders of the listed company	2,780,265,794.10	2,719,699,779.72		2.23

Note: The “reporting period” refers to the three-month period from the beginning of this quarter to the end of this quarter, the same below.

(B) Non-recurring profit or loss items and amounts

Unit: Yuan Currency: RMB

Items	Amount for the Reporting Period	Amount for the period from the beginning of the year to the end of the Reporting	Description

2023 Third Quarterly Report

		Period	
Gain and loss from disposal of non-current assets	-549.43	-549.43	
Tax refund or exemption from ultra vires approval or without official approval document or received occasionally	-		
Government grants included in profit or loss for the current period other than those closely relating to the normal business of enterprises and subject to a fixed amount or quantity under certain standard and in compliance with national policies	1,103,850.85	5,089,928.69	
Capital utilization fee received from non-financial enterprises included in current profit or loss	-		
Investments of subsidiaries, associates and joint ventures in which the investment cost was less than the profit at fair value of identifiable net assets of the investees at the time of acquisition	-		
Gain or loss on exchange of non-monetary assets	-		
Gain or loss on entrusted investments or assets under management	-		
Provision for impairment on assets due to force majeure events, such as natural disasters	-		
Gain or loss on debt restructuring	-		
Corporate restructuring costs, such as staff resettlement expenses, consolidated charges, etc.	-		

Gain or loss on transactions at unfair trading prices over their fair value	-		
Net gains or losses of subsidiaries for the current period from the beginning of the period to the date of consolidation arising from business consolidation under common control	-		
Gain or loss from other contingencies which are not related to the Company's normal operations	-		
Gain or loss on changes in fair value of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities, and investment income from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities, derivative financial liabilities and other debt investments, except for effective hedging transactions that are related to the Company's normal operation	2,689,601.75	17,139,413.10	
Reversal of the impairment provision for receivables and contract assets under independent impairment test	-		
Gain or loss on entrusted loans	-		
Gain or loss arising from changes in fair value of investment properties under fair value method on subsequent measurement	-		
Effect of one-off adjustment to	-		

current profit or loss according to the requirements of laws and regulations on tax and accounting on current profit or loss			
Custody fee income from custody operations	-		
Other non-operating income and expenses apart from the aforesaid items	-127,527.00	-249,919.31	
Other gain or loss items conforming to the definition of non-recurring gains or losses	-	229,656.04	
Less: Effect of income tax	549,002.33	3,328,767.56	
Impact of minority interests (after tax)	1,608.19	6,853.95	
Total	3,114,765.65	18,872,907.58	

Explanations on defining the non-recurring gain or loss items set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public - Non-Recurring Gains or Losses as recurring gain or loss items

Applicable Not applicable

(C) Description and reasons for the changes in key accounting data and financial indicators

Applicable Not applicable

Item name	Percentage of change (%)	Main reason(s)
Operating income - the Reporting Period	33.34	This was mainly due to the increase in the sales volume of relevant products as a result of the favourable national centralised procurement policies, which increased the penetration rate of the Company.
Net profit attributable to shareholders of the Company after non-recurring profit or loss - the Reporting Period	106.11	
Net cash flows from operating activities - Current Reporting Period	924.95	Cash flows from operating activities increased mainly due to ① the increase in sales revenue and the year-on-year increase in the corresponding sales collection; and ② the expiry of certain notes receivable during the Reporting Period.

2. Information of shareholders

(A) Total number of ordinary shareholders, preferred shareholders whose voting rights have been reinstated, and the shareholding of top ten shareholders

Unit: Share

Total number of ordinary shareholders at the end of the Reporting Period		4,961	Total number of shareholders of preferred shares with voting rights reinstated (if any) at the end of the Reporting Period	N/A			
Shareholding of top ten shareholders							
Name of shareholder	Nature of shareholder	Number of shares held	Shareholding percentage (%)	Number of shares held subject to trading restrictions	Number of Shares subject to trading restrictions that include lending shares for securities financing	Shares charged, tagged or frozen	
						Status of shares	Number
Shi Chunbao	Domestic natural person	114,840,685	29.940%	113,685,435	0	None	0
Yue Shujun	Domestic natural person	95,447,900	24.884%	95,447,900	0	None	0

2023 Third Quarterly Report

Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP)	Domestic non-state owned legal person	17,250,000	4.497%	0	-	Unknown	-
Industrial and Commercial Bank of China Limited - China-Europe Medical and Health Hybrid Securities Investment Fund	Others	8,424,808	2.196%	0	-	Unknown	-
China Bohai Bank Co., Ltd - China Securities Healthcare Reform Flexible Allocation Hybrid Securities Investment Fund	Others	3,554,971	0.927%	0	-	Unknown	-
Huatai Securities (Shanghai) Asset Management Co., Ltd. - The Bank of China - Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board	Others	2,688,523	0.701%	0	-	Unknown	-
Huang Dong	Domestic natural person	2,533,335	0.660%	0	-	Unknown	-
Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP)	Domestic non-state owned legal person	2,500,000	0.652%	0	-	Unknown	-
Jin Jie	Domestic natural person	2,474,604	0.645%	0	-	Unknown	-

2023 Third Quarterly Report

Industrial and Commercial Bank of China Limited - Dongfanghong Qiyuan Three-year holding period Hybrid Securities Investment Fund* (東方紅啓元三年持有期混合型證券投資基金)	Others	2,417,600	0.630%	0	-	Unknown	-
Shareholding of top ten shareholders not subject to trading restrictions							
Name of shareholder	Number of tradable shares held not subject to trading restrictions	Share class and number					
		Share class	Number				
Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP)	17,250,000	RMB-denominated ordinary shares	17,250,000				
Industrial and Commercial Bank of China Limited - China-Europe Medical and Health Hybrid Securities Investment Fund	8,424,808	RMB-denominated ordinary shares	8,424,808				
China Bohai Bank Co., Ltd - China Securities Healthcare Reform Flexible Allocation Hybrid Securities Investment Fund	3,554,971	RMB-denominated ordinary shares	3,554,971				
Huatai Securities (Shanghai) Asset Management Co., Ltd. - The Bank of China - Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board	2,688,523	RMB-denominated ordinary shares	2,688,523				
Huang Dong	2,533,335	RMB-denominated ordinary shares	2,533,335				

2023 Third Quarterly Report

Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP)	2,500,000	RMB-denominated ordinary shares	2,500,000
Jin Jie	2,474,604	RMB-denominated ordinary shares	2,474,604
Industrial and Commercial Bank of China Limited - Dongfanghong Qiyuan Three-year holding period Hybrid Securities Investment Fund* (東方紅啓元三年持有期混合型證券投資基金)	2,417,600	RMB-denominated ordinary shares	2,417,600
China Merchants Bank Co., Ltd. - Penghua Emerging Industry Hybrid Securities Investment Fund* (鵬華新興產業混合型證券投資基金)	2,069,028	RMB-denominated ordinary shares	2,069,028
Longwin Asset Management Co., Ltd. - Longwin Healthcare Preferred Phase 1 Private Securities Investment Fund* (龍贏醫療健康優選1期私募證券投資基金)	2,012,308	RMB-denominated ordinary shares	2,012,308
Description of connected relationship or acting in concert of the above shareholders	<p>1. As of the date of this announcement, Shi Chunbao and Yue Shujun are couple, Panmao and Panxin are the same controlling party. Apart from the above, the Company does not receive any statement from the top ten shareholders regarding the existence of connected relationship or agreement of acting-in-concert;</p> <p>2. The Company is not aware of the existence of connected relationship among shareholders of tradable shares, or if they are the concerted parties under the stipulation of Measures for the Administration of Disclosure of Shareholder Equity Changes of Listed Companies.</p>		

Description on participation in margin financing and securities lending and lending shares for securities financing by top ten shareholders and top ten shareholders not subject to trading restrictions (if any)	There are no preferred shareholders in the Company
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------

Note:

1. At the end of the Reporting Period, the number of shareholders of the Company' s A share was 4,944 and the number of registered shareholders of H shares was 17.
2. The number of shares held by Mr. Shi Chunbao, the de facto controller of the Company, includes restricted A shares and H shares not subject to trading restrictions.

3. Other notice

Other important information related to the operational conditions of the Company during the Reporting Period which requires the attention of the investors

Applicable Not applicable

On 14 September 2023, the Office of Joint Procurement of High-Value Medical Consumables of the State Organisation issued the Announcement on Centralised Volume-based Procurement of Intraocular Lens and Sports Medical Consumables of the State Organisation (No. 1)* (《國家組織人工晶體類及運動醫學類醫用耗材集中帶量採購公告（第1號）》), which sets out the product catalogue, procurement rules and procurement cycle of this procurement. The implementation of centralised volume-based procurement by the State has helped leading domestic enterprises to increase their market share. As a leading enterprise in orthopaedics, the Company will leverage on its advantages, actively respond to the call of national policies, timely track the market dynamics of the country and various provinces and cities, actively promote the construction of marketing network, further improve the market share, and achieve long-term and stable development in the field of orthopaedics.

4. Quarterly financial statements

(A) Type of auditor' s opinion

Applicable Not applicable

(B) Financial statements

CONSOLIDATED BALANCE SHEET

30 September 2023

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2023	31 December 2022
Current assets:		
Monetary funds	769,910,815.03	957,193,661.02
Settlement reserve		
Placements with banks and non-bank financial institutions		
Held-for trading financial assets	826,151,342.47	767,727,534.25
Derivative financial assets		
Notes receivable	120,689,271.55	278,639,012.00
Accounts receivable	532,938,123.91	488,746,494.02
Accounts receivable financing		
Prepayment	14,830,075.02	12,699,528.18
Premium receivable		
Reinsurance premium receivables		
Reserves for reinsurance contract receivables		
Other receivables	620,807.73	675,810.93

2023 Third Quarterly Report

Including: Interests receivables		
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	415,967,371.88	259,789,488.85
Contract assets		
Assets held- for-sale		
Non-current assets due within one year		
Other current assets	16,282,616.35	13,617,453.61
Total current assets	2,697,390,423.94	2,779,088,982.86
Non-current assets:		
Loans and advances		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments		
Other investments in equity instruments		
Other non- current financial assets		
Investment property		
Fixed assets	274,216,828.08	278,294,518.06

2023 Third Quarterly Report

Construction in progress	208,287,688.69	185,101,678.99
Productive biological assets		
Oil & gas assets		
Right-of-use assets	989,988.15	1,875,408.53
Intangible assets	137,589,893.32	138,167,738.59
Development expenditures		
Goodwill	13,359,553.09	
Long-term prepayments		
Deferred income tax assets	25,290,013.59	25,761,809.04
Other non-current assets	2,764,471.55	1,476,554.84
Total non-current assets	662,498,436.47	630,677,708.05
Total assets	3,359,888,860.41	3,409,766,690.91
Current liabilities:		
Short-term borrowings		
Borrowings from central banks		
Placements from banks and non-bank financial institutions		
Held-for-trading financial liabilities		
Derivative financial liabilities		
Notes payable		
Accounts payable	184,922,549.43	237,786,563.39
Advances received		

2023 Third Quarterly Report

Contract liabilities	78,953,501.92	85,681,592.64
Financial assets sold under repurchase agreement		
Deposits and placements from peers		
Brokerage for trading securities		
Brokerage for underwriting securities		
Employee remuneration payable	26,494,654.75	69,723,670.57
Taxes payable	31,967,403.11	53,550,224.66
Other payables	77,002,214.21	72,509,089.96
Including: Interests payable		
Dividends payable		
Handling fee and commission payables		
Reinsurance premium payables		
Held-for-sale liabilities		
Non-current liabilities due within one year	673,939.56	688,285.72
Other current liabilities	84,718,203.48	75,865,112.99
Total current liabilities	484,732,466.46	595,804,539.93
Non-current liabilities:		
Reserves for insurance contracts		

2023 Third Quarterly Report

Long-term borrowings		
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities		625,860.19
Long-term payables		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred income	83,406,088.20	85,757,219.55
Deferred income tax liabilities	9,852,420.49	7,879,291.52
Other non-current liabilities		
Total non-current liabilities	93,258,508.69	94,262,371.26
Total liabilities	577,990,975.15	690,066,911.19
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	383,568,500.00	384,280,000.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserve	1,044,799,419.83	1,051,228,272.24
Less: treasury shares		7,140,352.41

2023 Third Quarterly Report

Other comprehensive income		
Specific reserve		
Surplus reserve	154,599,501.79	154,599,501.79
General reserve		
Undistributed profits	1,197,298,372.48	1,136,732,358.10
Total equity attributable to owners (or equity attributable to shareholders) of the parent company	2,780,265,794.10	2,719,699,779.72
Minority interests	1,632,091.16	
Total owners' equity (or shareholders' equity)	2,781,897,885.26	2,719,699,779.72
Total liabilities and owners' equity (or shareholders' equity)	3,359,888,860.41	3,409,766,690.91

Person in charge of the Company: Shi Wenling Person in charge for accounting affairs of the Company: Li Yumei Person in charge of the accounting department: Li Yumei

Consolidated income statement

January to September 2023

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2023 (January to September)	First three quarters of 2022 (January to September)
1. Total operating revenue	792,155,559.31	759,964,308.26
Including: Operating revenue	792,155,559.31	759,964,308.26
Interest income		
Premiums gained		

Income from handling fee and commission		
2. Total operating cost	607,002,161.57	550,512,366.06
Including: Operating cost	232,370,997.62	198,475,858.69
Interest expense		
Handling fee and commission expense		
Surrender value		
Net amount of compensation payout		
Net amount of insurance contracts reserves withdrawn		
Policy dividend payment		
Reinsurance Expenses		
Taxes and surcharge	5,742,326.79	8,754,270.79
Selling expenses	233,751,182.69	230,167,966.03
Administrative expenses	28,910,652.58	24,677,613.84
Research and development expenses	114,743,907.65	105,014,400.73
Financial expenses	-8,516,905.76	-16,577,744.02
Including: Interest expenses	48,115.37	
Interest income	8,164,883.50	11,813,567.92
Add: Other gains	5,119,584.73	22,173,040.13
Investment income (losses are presented as “-”)	10,067,668.50	6,561,150.69
Including: Investment income from associates and joint ventures		
Gains from derecognition of financial assets measured at amortised cost		
Foreign exchange gains (losses are presented as “-”)		
Net profit on hedging exposure (losses are presented as “-”)		
Gains on changes of fair value (losses are presented as “-”)	7,071,744.60	6,539,410.97
Loss on credit impairment (losses are presented as “-”)	-8,302,884.20	-10,513,769.24
Loss on asset impairment (losses are presented as “-”)	-3,175,940.28	-2,912,398.06
Gains on disposal of assets (losses are presented as “-”)	-549.43	25,305.66

2023 Third Quarterly Report

3. Operating profit (losses are presented as “ - ”)	195,933,021.66	231,324,682.35
Add: Non-operating income	289,299.36	44,034.43
Less: Non-operating expenses	339,218.67	2,294,278.39
4. Gross profit (total losses are presented as “ - ”)	195,883,102.35	229,074,438.39
Less: income tax expenses	15,402,533.56	19,366,905.76
5. Net profit (net losses are presented as “ - ”)	180,480,568.79	209,707,532.63
(A) Classified by continuity of operation:		
1. Net profit for continuing operation (net losses are presented as “ - ”)	180,480,568.79	209,707,532.63
2. Net profit for ceased operation (net losses are presented as “ - ”)		
(B) Classified by ownership:		
1. Net profit attributable to the shareholders of the parent company (net losses are presented as “ - ”)	180,622,954.88	209,707,532.63
2. Non-controlling shareholders' profit or loss (net losses are presented as “ - ”)	-142,386.09	
6. Net other comprehensive income after tax		
(I) Net other comprehensive income after tax attributable to the owners of the parent company		
1. Other comprehensive income that cannot be reclassified into profit or loss		
(1) Changes in remeasurement on defined benefit plan		
(2) Other comprehensive income that cannot be transferred to profit and loss under equity method		
(3) Fair value change on other investments in equity instruments		
(4) Fair value change on credit risk of the enterprise		
2. Other comprehensive income that will be reclassified into profit or loss		

(1) Other comprehensive income that can be transferred to profit and loss under equity method		
(2) Fair value change on other debt investments		
(3) Amounts of financial assets reclassified into other comprehensive income		
(4) Provision on credit impairment on other debt investments		
(5) Reserves of cash flow hedging		
(6) Translation difference on financial statements denominated in foreign currencies		
(7) Others		
(II) Net other comprehensive income after tax attributable to non-controlling shareholders		
7. Total comprehensive income	180,480,568.79	209,707,532.63
(A) Total comprehensive income attributable to the owners of the parent company	180,622,954.88	209,707,532.63
(B) Total comprehensive income attributable to non-controlling shareholders	-142,386.09	
8. Earnings per share:		
(A) Basic earnings per share (yuan/share)	0.47	0.55
(B) Diluted earnings per share (yuan/share)	0.47	0.55

For business combination under common control conducted during the current period, the acquiree achieved a net profit of RMB0.00 before the combination; the acquiree achieved a net profit of RMB0.00 during the previous period.

Person in charge of the Company: Shi Wenling Person in charge for accounting affairs of the Company: Li Yumei Person in charge of the accounting department: Li Yumei

Consolidated cash flow statement

January to September 2023

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items		
-------	--	--

2023 Third Quarterly Report

	First three quarters of 2023 (January to September)	First three quarters of 2022 (January to September)
1. Cash flows from operating activities:		
Cash receipts from sale of goods and rendering of services	897,101,117.43	643,963,252.24
Net increase in the amounts of deposits from customers and placements from peers		
Net increase in amounts due to central banks		
Net increase in placements from other financial institutions		
Cash received from the premium of original insurance contract		
Net cash received from reinsurance business		
Net increase in policyholder deposits and amount for investment		
Cash received from interest, handling fee and commission		
Net increase in placements from banks and non-bank financial institutions		
Net increase in capital on business repurchased		
Net cash received on securities dealing agency services		
Receipts of tax refund		
Other cash receipts related to operating activities	15,977,407.49	31,641,477.11
Subtotal of cash inflow from operating activities	913,078,524.92	675,604,729.35
Cash payments for goods purchased and services received	314,980,645.94	231,644,127.24
Net increase in loans and advances from customers		
Net increase in amounts deposited in central bank and peers		
Cash payment on compensation payout in original insurance contract		
Net increase in placements with banks and non-bank financial institutions		
Cash payment on interest, handling fee and commission		

2023 Third Quarterly Report

Cash payment for policy dividend		
Cash paid to and on behalf of employees	186,436,115.59	146,133,791.96
Taxes paid	72,471,359.18	87,164,303.47
Other cash payments related to operating activities	325,441,246.23	287,031,448.40
Subtotal cash outflow from operating activities	899,329,366.94	751,973,671.07
Net cash flows from operating activities	13,749,157.98	-76,368,941.72
2. Cash flows from investing activities:		
Cash received from disinvestments	1,525,300,000.00	1,538,000,000.00
Cash received from return on investments	13,752,561.34	12,302,027.41
Net cash received from the disposal of fixed assets, intangible assets and other long-term assets		63,500.00
Net cash received from the disposal of subsidiaries and other business units		
Other cash receipts related to investing activities		
Subtotal of cash inflow from investing activities	1,539,052,561.34	1,550,365,527.41
Cash paid for acquiring fixed assets, intangible assets and other long-term assets	34,597,694.23	57,315,502.70
Cash payments for investments	1,579,000,000.00	2,028,000,000.00
Net increase in pledged loans		
Net cash payments for acquisitions of subsidiaries and other business units	6,989,298.50	
Other cash payments related to investing activities		
Subtotal of cash outflow from investing activities	1,620,586,992.73	2,085,315,502.70
Net cash flows from investing activities	-81,534,431.39	-534,949,975.29
3. Cash flows from financing activities:		
Cash received from investments		
Including: cash received by subsidiaries from non-controlling shareholders' investments		
Cash received from borrowings		
Other cash receipts related to financing activities		
Subtotal of cash inflow from financing activities		
Cash repayment of debts		

2023 Third Quarterly Report

Cash paid for distribution of dividends, profits or for interest expenses	120,056,940.50	50,040,811.74
Including: dividends and profit paid by subsidiaries to non-controlling shareholders		
Other cash payments related to financing activities	722,700.00	8,791,201.88
Subtotal of cash outflow from financing activities	120,779,640.50	58,832,013.62
Net cash flows from financing activities	-120,779,640.50	-58,832,013.62
4. Effect of foreign exchange rate changes on cash and cash equivalents	673,557.68	2,058,952.60
5. Net increase in cash and cash equivalents	-187,891,356.23	-668,091,978.03
Add: Opening balance of cash and cash equivalents	957,193,661.02	1,736,493,995.38
6. Closing balance of cash and cash equivalents	769,302,304.79	1,068,402,017.35

Person in charge of the Company: Shi Wenling Person in charge for accounting affairs of the Company: Li Yumei Person in charge of the accounting department: Li Yumei

Adjustments to the financial statements at the beginning of the year of the first implementation due to the first implementation of the new accounting standards or interpretation of accounting standards since 2023

Applicable Non applicable

The Board of Directors of Beijing Chunlizhengda Medical Instruments Co., Ltd.*

31 October 2023

* For identification purposes only